Storys zum Thema Pharma

WMDO SA - World Medical Device Organization

WMDO Announces 100th Online Training Course for Medical Device Professionals

Ecublens, Switzerland / Minneapolis, MN (ots) - WMDO (World Medical Device Organization), the leading global provider of innovative online training for medical device professionals, announced today that it has achieved its 100th online course. Excellent reviews from industry analysts, trade associations and users in recent months have enabled WMDO to leverage growing ...

Scobag Privatbank AG

Changes in Roche Shareholder Pool

Basel (ots) - The majority of the direct descendants of company founder Fritz Hoffmann-La Roche have decided to continue the shareholder pooling agreement existing since 1948 with a modified shareholder composition. A charitable foundation established by pool members has been admitted to the pool. Maja Oeri has decided to leave the pool. The pool therefore now has 45,01 % of the votes in Roche but will ensure ...

Helsinn Healthcare SA

FDA Agrees to Special Protocol Assessment (SPA) to Evaluate the Safety and Efficacy of a Fixed-Dose Combination (FDC) of Netupitant and Palonosetron in the Prevention of CINV

Lugano, Switzerland/Woodcliff Lake, NJ (ots) - Helsinn Group and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the safety and efficacy protocols for Phase III trials with an investigational oral fixed-dose combination of netupitant and palonosetron in the prevention ...

Pieris AG

Takeda San Francisco and Pieris Sign Anticalin® Therapeutic Collaboration

San Francisco, USA and Freising, Germany (ots) - Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin® scaffold technology to deliver protein therapeutic candidates to Takeda, both companies announced today. The deal initially will focus on first-in-class drug discovery efforts ...

Helsinn Healthcare SA

Helsinn Birex Pharmaceuticals Limited has been assigned certain international rights to Klean-Prep® by Helix BioPharma Corp.

Lugano, Switzerland (ots) - Helsinn Birex Pharmaceuticals Ltd, has been assigned world-wide rights, title and interest in Klean-Prep®, excluding Canada, and an exclusive license for the U.S. Helsinn, a pharmaceutical group based in Lugano, Switzerland today announced that it has entered into an agreement ...

Pevion Biotech AG

Pevion´s breakthrough candida vaccine demonstrates safety and immunogenicity in Phase I clinical study

Ittigen, Berne (ots) - Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women ...

BKW Energie AG

Lonza and BKW enter into partnership for energy procurement

Bern (ots) - Lonza AG in Visp has entered into a partnership with BKW FMB Energy Ltd (BKW) in the field of energy logistics and procurement management. Lonza plans to purchase its energy - around 500 GWh per year - on the free market in future, and has selected BKW as its partner of preference. BKW has contracted to support Lonza AG with its energy procurement strategy and sustainably implement the related ...

Helsinn Healthcare SA

Helsinn announces license agreement with Specialised Therapeutics for palonosetron in Australia / Leading anti-nausea drug available to Australian and New Zealand cancer patients

Lugoano, Switzerland/Melbourne, Australia (ots) - Australians can now access a new drug to prevent acute (and delayed phase) nausea and vomiting which may occur in cancer patients undergoing chemotherapy1. This follows an agreement between the Swiss pharmaceutical group Helsinn and Specialised Therapeutics ...

Helsinn Healthcare SA

Palonosetron more effective than granisetron in controlling nausea according to the protect study

Lugano (ots) - New data presented at the ESMO Milan 2010 Congress show a better control of nausea and vomiting with palonosetron versus granisetron in patients undergoing cisplatin or anthracycline plus cyclophosphamide based regimens. Palonosetron superior efficacy is statistically significant in nausea control, following Highly Emetogenic Chemotherapy, in the ...

Pieris AG

Pieris Signs Broad Collaboration with Sanofi-Aventis and Sanofi Pasteur to Develop Anticalin Therapeutics

Freising-Weihenstephan (ots) - Pieris AG announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), under which Pieris will apply its proprietary Anticalin technology to ...

Helsinn Healthcare SA

Helsinn announces the offical opening of its new R&D Centre of Excellence in Dublin

Lugano (ots) - The Minister for Finance, Mr. Brian Lenihan T.D. today performed the official opening of the centre which will play a significant role in Helsinn group's pipeline of new products. The Swiss pharmaceutical group Helsinn announced the official opening, performed today by the Minister for Finance, Mr. Brian Lenihan T.D, of its new R&D Centre of ...

Helsinn Healthcare SA

Helsinn and Mundipharma sign new contract for Palonosetron in Asian countries

Lugano (ots) - Helsinn's second-generation 5-HT3 RA Aloxi expands its presence in Asia through the Agreement signed with Mundipharma Helsinn Healthcare SA and Mundipharma International Corporation Ltd. announce the signature of a Distribution and Licensing Agreement for Helsinn's product palonosetron in Malesia, Philippines and Singapore. Aloxi® is a ...

Occlutech GmbH

Occlutech prevails in U.K. patent appeal by AGA Medical

Jena (ots) - In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent. AGA asked ...

Interpharma

Swiss pharmaceutical industry sets new standards in the protection of laboratory animals

Pieris AG

Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound / Anti-VEGF PRS-050 is first Anticalin tested in humans

Freising-Weihenstephan (ots) - Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the compound's safety and tolerability in patients with solid tumors. ...

Helsinn Healthcare SA

Helsinn Healthcare S.A. and Eisai Inc. Extend Relationship Enter U.S. Licence and Co-promotion Agreement for Potential New Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV)

Lugano, Switzerland/Woodcliff Lake, NJ, USA (ots) - Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the United ...

PregLem SA

PregLem announces positive phase III results for Esmya[TM]

Geneva (ots) - PEARL I trial meets primary efficacy and safety endpoints / PregLem preparing for submission to the European Medicines Agency in 2010 PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine ...

Helsinn Healthcare SA

Cancer supportive care: Oral Palonosetron approved in EU

Lugano (ots) - The second generation 5-HT3 receptor antagonist palonosetron, already approved as an intravenous solution formulation in more than 60 countries worldwide including US, EU and Japan, obtains the European Marketing Authorization for 0.5 mg oral capsules Palonosetron 0.5 mg soft gelatine capsule oral formulation has been approved by the EMA (European Medicine Agency) for the prevention of nausea and ...

Helsinn Healthcare SA

Helsinn and Vifor Pharma sign new contract for Gelclair in Switzerland

Lugano (ots) - New therapeutic option for the management of painful symptoms of oral mucositis in the oncology setting soon available for Swiss patients Helsinn, the pharmaceutical group based in Lugano, and Vifor Pharma, are pleased to announce that a Distribution & Licensing Agreement for Helsinn's product Gelclair in Switzerland has been signed recently. ...

Helsinn Healthcare SA

The 5-HT3 Receptor Antagonist Aloxi® launched in Japan

Lugano, Switzerland / Tokyo, Japan (ots) - Helsinn Healthcare SA, Switzerland, and Taiho Pharmaceutical Co., Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announce the launch of Aloxi® injection today. Aloxi was developed in Japan by Taiho in close cooperation with Helsinn, based on the license agreement between Taiho and Helsinn of January 2004, and its marketing ...

Gerresheimer AG

Good start to the year for Gerresheimer

Düsseldorf (ots) - - Group sales in the first quarter up 1.4% on like-for-like basis - Profit from operations grew by 34% to EUR 12.3m - Reiteration of guidance for the financial year 2010 Gerresheimer AG has got off to a good start in the new financial year. In the first quarter (December 2009 to February 2010), sales increased by 1.4% on a like-for-like basis and amounted to EUR 224.8m. ...

AmVac AG

AmVac AG registers progress with the RSV vaccine

Zug (ots) - The Swiss AmVac AG, a biopharmaceutical company located in Zug, has made significant advances in the manufacture and production of its vaccine candidate against RSV over the last few months. This vaccine candidate is based on the new Sendai vector technology for which Max-Planck-Innovations GmbH has acquired the exclusive licence. This technology, which has been developed by Prof. Wolfgang Neubert's ...

SYGNIS AG

SYGNIS announces nine months results of fiscal year 2009/2010

Heidelberg (ots) - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today reports financial results for the third quarter and the first nine months of the fiscal year 2009/2010 ended December 31, 2009. Financials - Cash including marketable securities amounted to EUR16.4 million as of December 31, 2009 (EUR26.0 million Q3 2008/2009). Long term financial liabilities ...

Debiopharm International SA

Debiopharm Group[TM] grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C -

Lausanne (ots) - Debiopharm Group[TM] (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture ...